These findings were notable because most drugs used in type 2 diabetes have not been shown to improve cardiovascular outcomes. Accordingly, there is growing interest in empagliflozin and the entire SGLT2 inhibitor class as drugs that could potentially change the manner in which we approach the ...
Type 2 DiabetesSGL2 InhibitorDehydrationGenitourinary InfectionSGLT2 inhibitors improve hyperglycemia with a decline in body weight and blood pressure, the outcomes touted to be of major importance in management of type 2 diabetes. However, the efficacy in lowering glycemia is very modest and imparts...
Clinical trials have consistently indicated that the use of an SGLT2 inhibitor can provide kidney protection through a decreased rate of decline in eGFR and reduced onset or progression of albuminuria [6,9,60,61]. The pioneering CREDENCE trial was the first to explore the influence of SGLT2 i...
In March 2017, dapagliflozin became the first SGLT2i approved for use in China. Additionally, sotagliflozin, the first dual SGLT2/1 inhibitor, improves glycated hemoglobin in adults with diabetes, with beneficial effects on body weight and blood pressure [16]. Table 1 Brief introduction to the...
Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis 2019, Clinical Therapeutics Citation Excerpt : Another novel class of oral glucose-lowering drugs is the SGLT2 inhibitors, which target the kidne...
SGLT2inhibitor use in the management of feline diabetes mellitus Review 作者:Cook, Audrey K.;Behrend, Ellen Abstract: Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors are routinely used in the management of human type 2 diabetes and have been shown to effectively mitigate hyperglycemia and reduce...
[关键词]糖尿病肾病;钠-葡萄糖协同转运蛋白2抑制剂;血管紧张素转化酶抑制剂;终末期肾脏疾病[中图分类号]R587.2;R692.9 [文献标识码]A [文章编号]1673-9701(2021)36-0189-04 Research progress of SGLT-2inhibitor in treating diabetic kidney disease WANG Heping LIAN Xu Department of Endocrinology,Hongqi ...
Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 (determining significant excretion of gluco
7. Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes[J].Nirschl AA;Wu G;Meng W;McCann PJ;Girotra RN;Ellsworth BA;Patel M;Morrison EP;Biller SA;Sher PM,Journal of Medicinal Chemistry...
Metformin and SGLT2 inhibitors together reduce the blood sugar levels considerably more effectively than either drug alone. Scientists from the Helmholtz Zentrum München, partner in the German Center for Diabetes Research, report in the journal 'Diabete